November 18, 2026

New FREEFLOW evidence on peripheral CTO crossing

Crossing comes first. Before many endovascular treatments can be delivered, clinicians need to get across the occlusion. Can we make that first step more predictable? That question drives our work with ProSonic™, our investigational ultrasonic system for crossing complex peripheral chronic total occlusions (CTOs).2,3

The latest results from FREEFLOW, our pivotal clinical study, add to the evidence behind that work. Dr Craig Walker, the study’s principal investigator and Founder and President of the Cardiovascular Institute of the South, presented the late-breaking data at NCVH’s inaugural Mid-America conference in Kansas City on 7 November 2026.1

FREEFLOW is a prospective, single-arm, multicentre study conducted under an Investigational Device Exemption (IDE). It enrolled 54 patients, with disease severity ranging from severe claudication (Rutherford classification, RC3) to minor tissue loss (RC5). Average lesion length was 162 mm, with 40 above-the-knee and 14 below-the-knee locations reported.1,2

The study reported 94% clinical success, defined as ProSonic™ FastWire® partially or fully crossing the CTO, facilitating delivery of a treatment device. Freedom from major serious adverse events (SAEs) related to use of ProSonic™ FastWire® was 100% at 30 days post-procedure.1

Technical success was reported as 98%, defined as device delivered to the CTO, full or partial CTO crossing, and system retrieval. At 30 days after the procedure, 52% of patients achieved an RC of 0 (asymptomatic).1

The data presented at NCVH were an initial, late-breaking presentation of the study data for all subjects, pending final analysis. Endpoint results are based on the per-protocol population (n=50). All other data are based on the intent-to-treat population (n=54).

Crossing creates access for the treatment that follows. We see ProSonic™ as a potential complement to existing endovascular therapies, and FREEFLOW adds to our understanding of how it performs in clinical use.

Our next regulatory step is a planned US FDA 510(k) submission in Q1 2027 for peripheral CTO crossing. The FREEFLOW results are intended to contribute clinical evidence to that submission.

At TCT 2026, Professor Faisal Sharif presented the technology behind ProSonic™. Built on our proprietary FastWire® technology, the system combines axial and radial harmonics in a dual-action lithotriptic mechanism. It is designed to cross complex lesions: once ultrasonically activated, it has the potential to cross thrombus, fibrous plaque and, most importantly, severe calcific plaque.4

We are also asking where the platform could take us next. Potential coronary applications and balloon-mediated intravascular lithotripsy remain under exploration. Our current clinical programme is focused on peripheral CTO crossing.3,4

To the patients who took part in FREEFLOW, and the investigators and study teams who made it possible, thank you. Your contribution is helping us build the evidence for the next stage of ProSonic™ development.

The ProSonic™ System is investigational and is not available for sale or commercial use in any market.

References

  1. Walker CM. FREEFLOW Pivotal Study: initial release of data. Late-breaking clinical trial presentation at: NCVH Mid-America; 7 November 2026; Kansas City, USA.
  2. Versono Medical Ltd. FREEFLOW. ClinicalTrials.gov identifier NCT06492733. https://clinicaltrials.gov/study/NCT06492733. Accessed 17 November 2026.
  3. Versono Medical. Clinical readiness and development. https://www.versono.life/clinical-readiness-and-development/. Accessed 17 November 2026.
  4. Sharif F. The ProSonic™ System; a New Vascular Platform Technology. Transforming the Endovascular Treatment of Complex Lesions and Chronic Total Occlusions (Versono Medical) [presentation]. TCT 2026: TCT Innovation 10, Innovation in Endovascular Therapies; 2 November 2026; San Diego, CA, USA.